Table 3 Univariate analysis for OS in younger GBM patients (age < 60 yrs) of TCGA database
| Variable | No.(%) | Median OS (months) | P | Median PFS (months) | P |
|---|---|---|---|---|---|
| Gender | 0.002 | 0.131 | |||
| Male | 78 (57.78) | 15.39 | 7.86 | ||
| Female | 57 (42.22) | 22.49 | 8.48 | ||
| LANCL2 gene status | 0.054 | 0.177 | |||
| Amplification | 33 (24.44) | 15.02 | 5.85 | ||
| No alteration | 102 (75.56) | 18.08 | 8.48 | ||
| EGFR gene status | 0.128 | 0.795 | |||
| Amplification | 56 (41.48) | 17.49 | 8.12 | ||
| No alteration | 79 (58.52) | 17.79 | 7.63 | ||
| LANCL2 and EGFR genes status | 0.054 | 0.177 | |||
| Co-amplification | 33 (24.44) | 15.02 | 5.85 | ||
| No alteration | 102 (75.56) | 18.08 | 8.48 |